Home Science European Union Approves Dovato as First-Line Treatment for HIV

European Union Approves Dovato as First-Line Treatment for HIV

European Union has approved Dovato, a two-drug pill developed by a UK company for fast-line treatment for HIV. According to the company, this will result in fewer long-term side effects compared to those of current treatments for the infection. As of now, HIV patients are required to take three or more antiretroviral everyday to keep the infection in check. However, as they grow older, these medications’ side effects can become more destressing along with those related to medicine for age-related conditions. In order to solve this problem, scientists from ViiV, the company behind the latest drug, have developed Dovato to replace the three drug treatments with just two piils. The European approval comes after FDA approved the drug back in April. Following the approval, patients over the age of 12 can now get the latest method of treatment given they aren’t susceptible to known resistance for lamivudine and dolutegravir. This latest approval marks another important step for the company which has been in the EU market since last year. Prior to this approval, Juluca is the other option HIV treatment was the company’s another two drug HIV treatment. However, Julaca is only approved as a maintenance therapy for adults who have previously taken other HIV medications.

European Union has approved Dovato, a two-drug pill developed by a UK company for fast-line treatment for HIV. According to the company, this will result in fewer long-term side effects compared to those of current treatments for the infection.

As of now, HIV patients are required to take three or more antiretroviral everyday to keep the infection in check. However, as they grow older, these medications’ side effects can become more destressing along with those related to medicine for age-related conditions. In order to solve this problem, scientists from ViiV, the company behind the latest drug, have developed Dovato to replace the three drug treatments with just two piils.

The European approval comes after FDA approved the drug back in April. Following the approval, patients over the age of 12 can now get the latest method of treatment given they aren’t susceptible to known resistance for lamivudine and dolutegravir.

This latest approval marks another important step for the company which has been in the EU market since last year. Prior to this approval, Juluca is the other option HIV treatment was the company’s another two drug HIV treatment. However, Julaca is only approved as a maintenance therapy for adults who have previously taken other HIV medications.

Related Articles